Baylor-Sammons Cancer Center

Dallas, Texas 75246

0 studies enrolling now · 24 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Aging, Antimetabolites, Antineoplastic, Breast Neoplasms, Cognition, Digestive System Diseases, Digestive System Neoplasms, Disease, Hodgkin, Endocrine Gland Neoplasms, Endocrine System Diseases

Studies at this site

• Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors — Stopped early
• A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy — Completed
• Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation — Completed
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) — Stopped early
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma — Completed
• A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer — Stopped early
• A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) — Completed
• Alvocidib Biomarker-driven Phase 2 AML Study — Stopped early
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) — Completed
• Selinexor Treatment of Refractory Myeloma — Completed
• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse — Stopped early
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma — Completed
• Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant — Running, not enrolling
• Selecting a Favorable KIR Donor in Unrelated HCT for AML — Completed
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic — Completed
• Trial of Romidepsin and Bortezomib for Multiple Myeloma — Stopped early
• Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma — Completed
• Cognition in the Study of Tamoxifen and Raloxifene — Completed
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer — Completed
• A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma — Completed
• A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL — Stopped early
• CT-011 MAb in DLBCL Patients Following ASCT — Completed
• Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab — Completed